| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1537-2995.2012.03865.X |
| P698 | PubMed publication ID | 22928875 |
| P2093 | author name string | Jerrold H Levy | |
| Charles Greenberg | |||
| P2860 | cites work | Diagnosis and classification of factor XIII deficiencies. | Q51553109 |
| A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. | Q51728855 | ||
| Interactions between factor XIII and the alphaC region of fibrinogen. | Q52846367 | ||
| Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. | Q52861770 | ||
| Coagulation factor XIII variants with altered thrombin activation rates. | Q53367600 | ||
| Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. | Q53858916 | ||
| FXIII polymorphisms, fibrin clot structure and thrombotic risk. | Q53878296 | ||
| A microtiter plate assay for factor XIII A-chain-fibrin interactions. | Q54633408 | ||
| Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms | Q28215367 | ||
| Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency | Q28303496 | ||
| Fibrin stabilization (factor XIII), fibrin structure and thrombosis | Q28305847 | ||
| Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. | Q30385934 | ||
| Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update | Q33364713 | ||
| Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion | Q33387901 | ||
| Factor XIII deficiency | Q33785637 | ||
| Molecular and genetic mechanisms of factor XIII A subunit deficiency | Q33915301 | ||
| Expression and release of the a and b subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells | Q34396084 | ||
| Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation | Q35570532 | ||
| Congenital blood coagulation factor XIII deficiency and perinatal management | Q36198765 | ||
| Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study | Q37657623 | ||
| Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination | Q37842688 | ||
| An update of the mutation profile of Factor 13 A and B genes. | Q37884728 | ||
| Management of pregnancy, labour and delivery in women with inherited bleeding disorders | Q37892650 | ||
| Factor XIII: a coagulation factor with multiple plasmatic and cellular functions | Q37899674 | ||
| Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited | Q37909229 | ||
| Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect | Q39190237 | ||
| Sushi domains in the B subunit of factor XIII responsible for oligomer assembly | Q39957742 | ||
| Factor XIII: inherited and acquired deficiency | Q40726148 | ||
| Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII | Q41249098 | ||
| Factor XIII in chronic inflammatory bowel diseases | Q41302317 | ||
| Isolation of a fibrin-binding fragment from blood coagulation factor XIII capable of cross-linking fibrin(ogen) | Q41765697 | ||
| The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking. | Q42326716 | ||
| Factor XIII--an under diagnosed deficiency--are we using the right assays? | Q42931085 | ||
| A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency | Q43570820 | ||
| Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency | Q43588755 | ||
| Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis | Q44487593 | ||
| Prevalence of the coagulation factor XIII polymorphism Val34Leu in women with recurrent miscarriage | Q44591021 | ||
| Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study | Q44693026 | ||
| Tyr204Phe and Val34Leu polymorphisms in two Brazilian ethnic groups and in patients with recurrent miscarriages | Q45143981 | ||
| Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency | Q45878100 | ||
| Intracranial haemorrhage in patients with congenital haemostatic defects | Q45879101 | ||
| Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management | Q45886878 | ||
| A Microtiter Assay for Factor XIII Using Fibrinogen and Biotinylcadaverine as Substrates | Q46459259 | ||
| A filter paper assay for transamidating enzymes using radioactive amine substrates | Q48024172 | ||
| Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients | Q48466483 | ||
| Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures | Q49151182 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1120-1131 | |
| P577 | publication date | 2012-08-28 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Biology of Factor XIII and clinical manifestations of Factor XIII deficiency | |
| P478 | volume | 53 |
| Q93181359 | Acquired factor XIII deficiency: A review |
| Q48680995 | Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samples. |
| Q35920828 | Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants |
| Q50099821 | Antifibrinolytic Therapy and Perioperative Considerations |
| Q37185291 | Coagulation during elective neurosurgery with hydroxyethyl starch fluid therapy: an observational study with thromboelastometry, fibrinogen and factor XIII |
| Q43865957 | Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations |
| Q34473794 | Cystamine preparations exhibit anticoagulant activity |
| Q38808158 | Diagnosis of factor XIII deficiency |
| Q90101130 | Effect of early administration of coagulation factor XIII on fistula after pancreatic surgery: the FIPS randomized controlled trial |
| Q42182012 | Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency |
| Q33944224 | Factor XIII activity mediates red blood cell retention in venous thrombi |
| Q45857147 | Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations |
| Q43416132 | Fibrinogen and FXIII dose response effects on albumin-induced coagulopathy |
| Q39115602 | In vitro secretion deficits are common among human coagulation factor XIII subunit B missense mutants: correlations with patient phenotypes and molecular models |
| Q88830577 | Molecular Basis of Congenital Factor XIII Deficiency in Iran |
| Q47767397 | Mutations in TGM6 induce the unfolded protein response in SCA35. |
| Q36906072 | New developments in the management of congenital Factor XIII deficiency |
| Q36719655 | Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals |
| Q58735789 | Optimizing transfusion strategies in damage control resuscitation: current insights |
| Q36529548 | Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel |
| Q92433851 | Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity |
| Q31139049 | Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data |
| Q47228028 | Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. |
| Q51016864 | [Factor XIII : Pharmacodynamic and pharmacokinetic characteristics]. |
Search more.